Screener
Trevi Therapeutics, Inc. TRVI Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 14,912 | 11,470 |
| Loss from operations | (14,912) | (11,470) |
| Other income (expense): | ||
| Interest income, net | 1,696 | 1,125 |
| Other income (expense), net | 4 | (6) |
| Total other income, net | 1,700 | 1,119 |
| Loss before income taxes | (13,212) | (10,351) |
| Income tax benefit | (20) | (11) |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s interest income?
- Trevi Therapeutics, Inc. (TRVI) reported interest income of $1.7M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s interest income changed year-over-year?
- Trevi Therapeutics, Inc.'s interest income increased by 50.8% year-over-year, from $1.13M to $1.7M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Trevi Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude